INOVIO Reports Inducement Grant Under Inducement Plan
INOVIO Reports Inducement Grant Under Inducement Plan . (MENAFN - PR Newswire) 
  
  
 
 
 
 
 
 PLYMOUTH MEETING, Pa., Nov. 29, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO ),a biotechnology company focused on developing and commercializing DNA medicines ...
América - MenaFN
(MENAFN- PR Newswire)

PLYMOUTH MEETING, Pa., Nov. 29, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO ),

a biotechnology company focused on developing and commercializing DNA medicines to

help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made

an equity grant to

a newly hired employee

under its 2022 Inducement Plan (the "Inducement Plan").

The Compensation Committee of INOVIO's Board of Directors has approved

the

award of an option to purchase 1,666

shares of common stock with a grant date of November

30, 2024

(the "Grant Date"), to a

newly

hired employee in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock option has an exercise price of $4.32, the closing price of INOVIO's common stock on November 29, 2024 (the last trading date preceding the Grant Date, which is not a trading day). The stock option will vest and become exercisable with respect to one-fourth of the shares underlying the stock option on the Grant Date, and an additional one-fourth of the shares underlying the stock option on the first, second, and third anniversaries of the Grant Date. The vesting of the stock option will be subject to the employee's continued employment with INOVIO on the applicable vesting dates. This award is subject to the terms and conditions of a stock option agreement

under the Inducement Plan.

About INOVIO

INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit .

Contacts

Media: Jennie Willson, (267) 429-8567, [email protected]

Investors: Thomas Hong, (267) 440-4298, [email protected]

SOURCE INOVIO Pharmaceuticals, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE? 440k+Newsrooms &Influencers 9k+Digital MediaOutlets 270k+JournalistsOpted In GET STARTED
Jordania
https://menafn.com/images/Menafn_SmallLogo.jpg
https://menafn.com/1108940368/INOVIO-Reports-Inducement-Grant-Under-Inducement-Plan
2024-11-29
rss
(MENAFN - PR Newswire) 
  
  
 
 
 
 
 
 PLYMOUTH MEETING, Pa., Nov. 29, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO ),a biotechnology company focused on developing and commercializing DNA medicines ...
INOVIO Reports Inducement Grant Under Inducement Plan